Mazdutide dosage

What Mazdutide is

Mazdutide is a once-weekly peptide that activates both the GLP-1 and glucagon receptors. It was approved in China in June 2025 for long-term weight management and in September 2025 for glycaemic control in type 2 diabetes, and it remains investigational in the United States, where phase 2 trials have been run. Randomized trials have reported body-weight and HbA1c reductions versus placebo or dulaglutide, with gastrointestinal events the most common adverse events; this entry summarizes them for research reference only.

Mazdutide is a long-acting synthetic analogue of oxyntomodulin with a fatty-acyl moiety, designed to activate both the GLP-1 receptor and the glucagon receptor ^8. Receptor pharmacology The phase 1b report describes potent binding to human and mouse GLP-1 and glucagon receptors in vitro, improved glucose control in mice, and body-weight reduction in both glucagon-receptor and GLP-1-receptor knockout mice, indicating… How it works →

Schedules by time period

study arms from registered trials, laid out week by week. Each bar is what the label states or what investigators gave participants; none is a recommendation.

Doses given in human trials

• In GLORY-1 (NCT05607680), Chinese adults with overweight or obesity were randomized 1:1:1 to mazdutide 4 mg, mazdutide 6 mg or placebo, once weekly, for 48 weeks ^1.
• In GLORY-2 (NCT06164873), participants were randomized 2:1 to once-weekly subcutaneous mazdutide 9 mg (n=308) or placebo (n=154), with a reduced-calorie diet and increased physical activity, for 60 weeks ^5.
• In the phase 3 monotherapy trial in type 2 diabetes, 320 participants were randomized 1:1:1 to weekly subcutaneous mazdutide 4 mg or 6 mg or placebo for 24 weeks, followed by 24 weeks of extended mazdutide treatment ^3.
• In DREAMS-2, 731 participants with type 2 diabetes on oral agents were randomized 1:1:1 to mazdutide 4 mg, mazdutide 6 mg or dulaglutide 1.5 mg for 28 weeks ^4.
• In the US phase 2 trial (NCT06124807), participants were randomized 3:2:3:3 to once-weekly subcutaneous placebo or mazdutide 3 to 6 mg, 10 mg or 16 mg for 48 weeks; the 3 to 6 mg group maintained 3 mg from week 4 to week 32 before moving to 6 mg ^7.
• In the Chinese phase 2 trial (NCT04904913), participants were randomized 3:1:3:1:3:1 to once-weekly mazdutide 3 mg, 4.5 mg, 6 mg or matching placebo, with a 24-week interim analysis ^6.
• In the phase 1b study (NCT04440345), participants were randomized 2:1 to once-weekly subcutaneous IBI362 or placebo in three cohorts for 12 weeks, with stepwise 4-week increases to 3.0 mg, 4.5 mg or 6.0 mg ^8.
• In the phase 1b type 2 diabetes study (NCT04466904), 43 patients received once-weekly IBI362 (3.0 mg, 4.5 mg or 6.0 mg), placebo or open-label dulaglutide 1.5 mg subcutaneously for 12 weeks ^9.

How long did human studies run?

• GLORY-1: 48 weeks; GLORY-2: 60 weeks ^1,5.
• Type 2 diabetes phase 3: 24 weeks plus a 24-week extension (placebo-controlled) and 28 weeks (DREAMS-2) ^3,4.
• US phase 2: 48 weeks, primary endpoint at 32 weeks ^7.

Who was excluded from the studies

• The US phase 2 trial excluded adults with type 2 diabetes ^7.
• GLORY-1 enrolled adults aged 18 to 75 with BMI 28 or higher, or 24 to below 28 with a weight-related coexisting condition ^1.
• No contraindication list from a national label was reviewed ^2.

Side effects reported in studies

• Vomiting
  53.1% vs 1.3% placebo · GLORY-2, mazdutide 9 mg, 60 weeks ⁵
• Nausea
  46.9% vs 3.2% placebo · GLORY-2, mazdutide 9 mg, 60 weeks ⁵
• Diarrhoea
  39.4% vs 6.5% placebo · GLORY-2, mazdutide 9 mg, 60 weeks ⁵
• Adverse events leading to discontinuation
  2.9% vs 0% placebo · GLORY-2, mazdutide 9 mg ⁵
• Adverse events leading to discontinuation
  1.5% (4 mg), 0.5% (6 mg) vs 1.0% placebo · GLORY-1, 48 weeks ¹
• Discontinuation due to adverse events
  Highest with 16 mg (20%) · US phase 2, adults without type 2 diabetes ⁷
• Heart-rate increase
  More prominent in the 6.0 mg cohort (numeric rates not given) · Phase 1b, Chinese adults with overweight or obesity, 12 weeks ⁸
• Anti-drug antibodies
  2 participants (one each in the 3.0 mg and 4.5 mg cohorts) · Phase 1b, 12 weeks ⁸

Mazdutide draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

sizes on the market

5 mg10 mg

2 · Water added

1 mL2 mL3 mL5 mL

3 · Amount per draw

mcgmg

4 · Syringe

30u50u100u

Your mix

10 mg + 2 mL water = 5 mg/mL

10 units holds 0.5 mg (500 mcg)

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	20	—
1 mL	10	—
1.5 mL	6.667	—
2 mL	5	—
2.5 mL	4	—
3 mL	3.333	—
5 mL	2	—

Supplies and handling

• Lyophilized vial
  Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
• Sterile diluent
  The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
• Graduated syringes
  Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
• Alcohol prep pads
  For wiping vial stoppers before each puncture.
• Nitrile gloves
  Clean gloves for aseptic handling.
• Sharps container
  Puncture-resistant container for used needles.

Storage

No FDA-approved storage instructions exist. Research material should be handled according to the supplier's documentation and certificate of analysis.

• Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
• Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
• Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent

The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.

Shook the vial and it foamed

Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.

The solution is cloudy or has particles

Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.

The powder cake looks melted or shrunken before reconstitution

This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.

Liquid sprayed back when the needle was removed

Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status

Approved in China in June 2025 (Xinermei), together with diet and physical activity, for long-term weight management in adults with BMI of 28 or higher, or 24 or higher with at least one weight-related comorbidity, and in September 2025 for glycaemic control in adults with type 2 diabetes, according to a journal summary of the approvals ^2. Not approved by the FDA; an openFDA Drugs@FDA query returned no application record ^10, and a US phase 2 trial was completed ^7.

United States (FDA)

Not approved; an openFDA Drugs@FDA query for mazdutide returned no application record ^10. A US phase 2 trial (NCT06124807) has been completed ^7.

Sport (WADA)

Mazdutide is not named on the WADA 2026 Prohibited List ^12. Class S0 covers substances with no current approval by any governmental regulatory health authority for human therapeutic use ^12; mazdutide has been approved in China ^2, so whether S0 applies depends on that approval, and athletes should seek WADA or national anti-doping guidance.

Status varies by country and changes over time. How we describe regulatory status.

Mazdutide compared with related compounds

Frequently asked questions

References

1. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1) N Engl J Med. 2025
2. Mazdutide: First Approval Drugs. 2025
3. Mazdutide versus placebo in Chinese adults with type 2 diabetes Nature. 2026
4. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes (DREAMS-2) Nature. 2026
5. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial JAMA. 2026
6. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity Nat Commun. 2023
7. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial Lancet Diabetes Endocrinol. 2026
8. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study EClinicalMedicine. 2021
9. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes Nat Commun. 2022
10. Drugs@FDA application data queried through openFDA for mazdutide (no matching application record returned on 23 October 2026) openFDA / Drugs@FDA. 2026
11. PubChem compound record for mazdutide (CID 167312357; CAS 2259884-03-0) PubChem. 2026
12. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
13. A Study of IBI362 in Participants With Obesity or Overweight (GLORY-1) ClinicalTrials.gov. 2024
14. A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise (DREAMS-1) ClinicalTrials.gov. 2024
15. A Study of IBI362 in Participants With Type 2 Diabetes (DREAMS-2) ClinicalTrials.gov. 2024